ARTICLE | Clinical News
Pristiq desvenlafaxine: Phase III data
January 4, 2016 8:00 AM UTC
Top-line data from a double-blind, international Phase III trial in 363 MDD patients ages 7-17 showed that a once-daily sustained-release formulation of oral Pristiq missed the primary endpoint of imp...